Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors

Neuropharmacology

Volumn 46, Issue 7, 2004, Pages 966-973

  Urigüen, Leyre ^a   Pérez Rial, Sandra ^a   Ledent, Catherine ^b   Palomo, Tomás ^a   Manzanares, Jorge ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Anxiety; Anxiety like behaviour; Benzodiazepine; Buspirone; Cannabinoid CB1 receptor; Knockout mice

Indexed keywords

ANXIOLYTIC AGENT; BROMAZEPAM; BUSPIRONE; CANNABINOID 1 RECEPTOR; CORTICOSTERONE; PROOPIOMELANOCORTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ANXIETY DISORDER; ARTICLE; BRAIN REGION; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DARKNESS; DELETION MUTANT; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; EMOTION; GENE EXPRESSION; HYPOPHYSIS; IMMOBILIZATION STRESS; LIGHT; MALE; MAZE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEFICIENCY; PROTEIN DETERMINATION; PROTEIN FUNCTION; REGULATORY MECHANISM; SOCIAL INTERACTION; TASK PERFORMANCE; WILD TYPE;

EID: 1842664350     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2004.01.003     Document Type: Article

References (26)

1. Arborelius L., Owens M.J., Plotsky P.M., Nemeroff C.B. The role of corticotropin-releasing factor in depression and anxiety disorders. J. Endocrinol. 160:1999;1-12.
2. Berrendero F., Maldonado R. Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol. Psychopharmacology. 163:2002;111-117.
3. Corchero J., Fuentes J.A., Manzanares J. Chronic administration with the cannabinoid receptor agonist CP-55,940 regulates corticotropin releasing factor and proopiomelanocortin gene expression in the hypothalamus and pituitary gland of the rat. Life Sci. 64:1999;905-911.
4. 1 cannabinoid receptor on anxiety. Eur. J. Neurosci. 16:2002;1395-1398.
5. Heim C., Ehlert U., Hellhammer D.H. The potential role of hypocortisolism in the pathophysiology of stress-related bodily disorders. Psychoneuroendocrinology. 25:2000;1-35.
6. Hoffman A.F., Lupica C.R. Mechanisms of cannabinoid inhibition of GABA(A) synaptic transmission in the hippocampus. J. Neurosci. 20:2000;2470-2479.
7. Kathuria S., Gaetani S., Fegley D., Valiño F., Duranti A., Tontini A., Mor M., Tarzia G., La Rana G., Calignano A., Giustino A., Tattoli M., Palmery M., Cuomo V., Piomelli D. Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. 9:2003;76-81.
8. 1 receptor knockout mice. Science. 283:1999;401-404.
9. Low K., Crestani F., Keist R., Benke D., Brunig I., Benson J.A., Fritschy J.M., Rulicke T., Bluethmann H., Mohler H., Rudolph U. Molecular and neuronal substrate for the selective attenuation of anxiety. Science. 290:2000;131-134.
10. 1 cannabinoid receptor knockout mice: correlation with behaviour. Eur. J. Neurosci. 15:2002;1178-1186.
11. Manzanares J., Corchero J., Romero J., Fernandez-Ruiz J.J., Ramos J.A., Fuentes J.A. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol. Sci. 20:1999a;287-294.
12. Manzanares J., Corchero J., Fuentes J.A. Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of delta(9)-tetrahydrocannabinol in rats. Brain Res. 21:1999b;173-179.
13. Marsicano G., Wotjak C.T., Azad S.C., Bisogno T., Rammes G., Cascio M.G., Hermann H., Tang J., Hofmann C., Zieglgansberger W., Di Marzo V., Lutz B. The endogenous cannabinoid system controls extinction of aversive memories. Nature. 418:2002;530-534.
14. 1 cannabinoid receptors in emotional behaviour. Psychopharmacology. 159:2002;379-387.
15. 1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport. 20:1997;491-496.
16. Navarro M., Carrera M.R.A., Fratta W., Valverde O., Cossu G., Fattore L., Chowen J.A., Gómez R., del Arco I., Villanua M.A., Maldonado R., Koob G.F., Rodríguez de Fonseca F. Functional interaction between opioid and cannabinoid receptors in drug self-administration. J. Neurosci. 21:2001;5344-5350.
17. Oliva J.M., Ortiz S., Palomo T., Manzanares J. Behavioural and gene transcription alterations induced by spontaneous cannabinoid withdrawal in mice. J. Neurochem. 85:2003;94-104.
18. Rodriguez de Fonseca F., Rubio P., Menzaghi F., Merlo-Pich E., Rivier J., Koob G.F., Navarro M. Corticotropin-releasing factor (CRF) antagonist [D-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats. J. Pharmacol. Exp. Ther. 276:1996;56-64.
19. Rodriguez de Fonseca F., Carrera M.R., Navarro M., Koob G.F., Weiss F. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science. 276:1997;2050-2054.
20. 1 cannabinoid receptor knockout mice. Proc. Natl. Acad. Sci. USA. 96:1999;5786-5790.
21. Tsou K., Mackie K., Sanudo-Pena M.C., Walker J.M. Cannabinoid CB1 receptors are localized primarily on cholecystokinin-containing GABAergic interneurons in the rat hippocampal formation. Neuroscience. 93:1999;969-975.
22. Valverde O., Ledent C., Beslot F., Parmentier M., Roques B.P. Reduction of stress-induced analgesia but not of exogenous opioid effects in mice lacking CB1 receptors. Eur. J. Neurosci. 12:2000;533-539.
23. Weidenfeld J., Feldman S., Mechoulam R. Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat. Neuroendocrinology. 59:1994;110-112.
24. Young S., Bonner T., Brann. Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain. Proc. Natl. Acad. Sci. USA. 83:1986;9827-9831.
25. 1 receptor knockout mice. Proc. Natl. Acad. Sci. USA. 96:1999;5780-5785.
26. Zuardi A.W., Shirakawa I., Finkelfarb E., Karniol I.G. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl). 3:1982;245-250.